How to get your corporate R&D to operate like a startup

By Chris Newmarker | May 18, 2020

innovation corporate R&D departments lightbulb

[Photo by Ameen Fahmy on Unsplash]

Too much bureaucracy often leaves corporate R&D departments hamstrung.

It’s little wonder that biotechs were responsible for 38 of the 59 new therapies approved in 2018 compared with 21 for the big pharmaceutical companies, according to Biotechnology Innovation Organization research cited in a recent Harvard Business Review article.

The authors of the HBR article were Harvard Medical School professor Jeff Karp, who leads a biomedical research laboratory, and Ken Banta, who served as a senior executive in several large global biopharma companies and now runs a C-suite consultancy. Go to HBR and read their advice on how big companies can make their R&D groups more effective.

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].